Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Zhao, Fung ^a,b   Siu, Michelle K Y ^a   Jiang, LiLi ^c   Tam, Kar Fai ^a   Ngan, Hextan Y S ^a   Le, Xiao Feng ^d   Wong, Oscar G W ^a   Wong, Esther S Y ^a   Gomes, Ana R ^b   Bella, Laura ^b   Khongkow, Pasarat ^b   Lam, Eric W F ^b   Cheung, Annie N Y ^a,e  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c SICHUAN UNIVERSITY   (China)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e THE UNIVERSITY OF HONG KONG SHENZHEN HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FORKHEAD BOX PROTEIN M1; FORKHEAD TRANSCRIPTION FACTOR; KIF2C ENZYME; KINESIN; PACLITAXEL; PROTEIN P53; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FOXM1 PROTEIN, HUMAN; KIF2C PROTEIN, HUMAN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL DEATH; CELL INVASION; CELL MIGRATION; CELLULAR PARAMETERS; CHEMOSENSITIVITY; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DOWN REGULATION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MITOTIC CATASTROPHE; OVARY CANCER; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN TARGETING; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL MOTION; DRUG EFFECTS; DRUG RESISTANCE; FOLLOW UP; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE-FREE SURVIVAL; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; FORKHEAD TRANSCRIPTION FACTORS; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KINESIN; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84912051474     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113478     Document Type: Article

References (29)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, et al. (2003) Cancer statistics, 2003. CA Cancer J Clin; 53(1): 5-26
2. Burger RA (2008) A new model of ovarian carcinogenesis may influence early detection strategies. Am J Obstet Gynecol; 198(4): 349-50
3. Myatt SS, Lam EW (2007) The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer; 7(11): 847-59
4. Koo CY, Muir KW, Lam EW (2012) FOXM1: From cancer initiation to progression and treatment. Biochim Biophys Acta; 1819(1): 28-37
5. Katoh M (2004) Human FOX gene family (Review). Int J Oncol; 25(5): 1495-500
6. Pilarsky C, Wenzig M, Specht T, Saeger HD, Gru? tzmann R (2004) Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia; 6(6): 744-50
7. Francis RE, Myatt SS, Krol J, Hartman J, Peck B, et al. (2009) FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. Int J Oncol; 35(1): 57-68
8. Kwok JM, Peck B, Monteiro LJ, Schwenen HD, Millour J, et al. (2010) FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res; 8(1): 24-34
9. Millour J, de Olano N, Horimoto Y, Monteiro LJ, Langer JK, et al. (2011) ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance. Molecular cancer therapeutics; 10(6): 1046-58
10. Jiang L, Siu MK, Wong OG, Tam KF, Lu X, et al. (2011) iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe. Clin Cancer Res; 17(21): 6924-33
11. Foster H, Coley HM, Goumenou A, Pados G, Harvey A, et al. (2010) Differential expression of mTOR signalling components in drug resistance in ovarian cancer. Anticancer research; 30(9): 3529-34
12. Siu MK, Wong ES, Chan HY, Kong DS, Woo NW, et al. (2010) Differential expression and phosphorylation of Pak1 and Pak2 in ovarian cancer: effects on prognosis and cell invasion. Int J Cancer; 127(1): 21-31
13. Zhao F, Siu MK, Jiang L, Tam KF, Ngan HY, et al. (2011) Overexpression of dedicator of cytokinesis I (Dock180) in ovarian cancer correlated with aggressive phenotype and poor patient survival. Histopathology; 59(6): 1163-72
14. Liao X, Siu MK, Au CW, Wong ES, Chan HY, et al. (2009) Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis, cell invasion and differentiation. Carcinogenesis; 30(1): 131-40
15. Kwok JM, Myatt SS, Marson CM, Coombes RC, Constantinidou D, et al. (2008) Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Molecular cancer therapeutics; 7(7): 2022-32
16. Chan DW, Hui WW, Cai PC, Liu MX, Yung MM, et al. (2012) Targeting GRB7/ERK/FOXM1 signaling pathway impairs aggressiveness of ovarian cancer cells. PLoS One; 7(12): e52578
17. Hamroun D, Kato S, Ishioka C, Claustres M, Béroud C, et al. (2006) The UMD TP53 database and website: update and revisions. Hum Mutat; 27(1): 14-20
18. Wolf JK, Mills GB, Bazzet L, Bast RC Jr, Roth JA, et al. (1999) Adenovirusmediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status. Gynecol Oncol; 75(2): 261-6
19. Yamakawa N, Takahashi A, Mori E, Imai Y, Furusawa Y, et al. (2008) High LET radiation enhances apoptosis in mutated p53 cancer cells through Caspase- 9 activation. Cancer science; 99(7): 1455-60
20. Wonsey DR, Follettie MT (2005) Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res; 65(12): 5181-9
21. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, et al. (2004) Cell death by mitotic catastrophe: a molecular definition. Oncogene; 23(16): 2825-37
22. Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, et al. (1998) Mutations of mitotic checkpoint genes in human cancers. Nature; 392(6673): 300-3
23. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science; 282(5393): 1497-501
24. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B (1999) 14-3- 3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature; 401(6753): 616-20
25. Sharp DJ, Rogers GC, Scholey JM (2000) Microtubule motors in mitosis. Nature; 407(6800): 41-7
26. Maney T, Hunter AW, Wagenbach M, Wordeman L (1998) Mitotic centromere-associated kinesin is important for anaphase chromosome segregation. The Journal of cell biology; 142(3): 787-801
27. Shimo A, Tanikawa C, Nishidate T, Lin ML, Matsuda K, et al. (2008) Involvement of kinesin family member 2C/mitotic centromere-associated kinesin overexpression in mammary carcinogenesis. Cancer science; 99(1): 62-70
28. Nakamura Y, Tanaka F, Haraguchi N, Mimori K, Matsumoto T, et al. (2007) Clinicopathological and biological significance of mitotic centromere-associated kinesin overexpression in human gastric cancer. British journal of cancer; 97(4): 543-9
29. Ganguly A, Yang H, Cabral F (2011) Overexpression of mitotic centromereassociated Kinesin stimulates microtubule detachment and confers resistance to paclitaxel. Molecular cancer therapeutics; 10(6): 929-37